Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL.
Center for International Blood and Marrow Transplant Research, Department of Medicine, and.
Blood Adv. 2019 Sep 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226.
Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT-comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range, <1-99 days]; RIC/NMA, 21 days [range, <1-100 days]; < .001). Patients receiving MAC were more likely to experience at least 1 bacterial infection by day 100 (MAC, 46% [95% confidence interval (CI), 43-49]; RIC/NMA, 37% [95% CI, 34-41]; = .0004), whereas at least a single viral infection was more prevalent in the RIC/NMA cohort (MAC, 34% [95% CI, 31-37]; RIC/NMA, 39% [95% CI, 36-42]; = .046). MAC remained a risk factor for bacterial infections in multivariable analysis (relative risk, 1.44; 95% CI, 1.23-1.67; < .0001). Moreover, the rate of any infection per patient-days at risk in the first 100 days (infection density) after alloHCT was greater for the MAC cohort (1.21; 95% CI, 1.11-1.32; < .0001). RIC/NMA was associated with reduced infections, especially bacterial infections, in the first 100 days after alloHCT.
推测,与清髓性预处理(MAC)方案相比,异基因造血细胞移植(alloHCT)中的减低强度/非清髓性预处理(RIC/NMA)可导致感染减少;然而,现有证据有限。在这项国际血液和骨髓移植研究中心的研究中,评估了 1755 例处于完全缓解期的初治急性髓性白血病(AML)且年龄≥40 岁的患者在 T 细胞补充 alloHCT 后 100 天内发生的感染。与接受 MAC(n=978)的患者相比,接受 RIC/NMA(n=777)的患者年龄更大且移植时间更新;然而,两组在卡氏功能状态评分、HCT 合并症指数和细胞遗传学风险方面相似。1045 例(59.5%)患者发生 1 次或更多次感染(MAC:595 [61%];RIC/NMA:450 [58%]; =.21),中位至首次感染时间在 MAC 预处理后更早(MAC:15 天[范围:<1-99 天];RIC/NMA:21 天[范围:<1-100 天]; <.001)。在第 100 天,MAC 患者更有可能至少发生 1 次细菌感染(MAC:46%[95%置信区间(CI):43-49];RIC/NMA:37%[95% CI:34-41]; =.0004),而 RIC/NMA 组中至少发生 1 次病毒感染更常见(MAC:34%[95% CI:31-37];RIC/NMA:39%[95% CI:36-42]; =.046)。多变量分析中 MAC 仍然是细菌感染的危险因素(相对风险,1.44;95% CI:1.23-1.67; <.0001)。此外,alloHCT 后第 100 天(感染密度)内每位患者的风险感染率(患者-天)在 MAC 队列中更高(1.21;95% CI:1.11-1.32; <.0001)。RIC/NMA 与 alloHCT 后前 100 天内感染减少相关,尤其是细菌感染。